C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates

Company Performance - C4 Therapeutics reported a quarterly loss of $0.37 per share, better than the Zacks Consensus Estimate of a loss of $0.48, and an improvement from a loss of $0.41 per share a year ago, representing an earnings surprise of 22.92% [1] - The company posted revenues of $7.24 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 103.03%, compared to revenues of $3.04 million in the same quarter last year [2] - Over the last four quarters, C4 Therapeutics has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - C4 Therapeutics shares have declined approximately 60.8% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.44 on revenues of $7.25 million, and for the current fiscal year, it is -$1.74 on revenues of $22.72 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which C4 Therapeutics belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact C4 Therapeutics' stock performance [5]